ATYR (aTyr Pharma) Valuation Rank


ATYR aTyr Pharma Inc ATYR
14 GF Score
Price $0.53
GF Value $0.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is aTyr Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

aTyr Pharma Valuation Rank Related Terms

ATYR
14GF Score
aTyr Pharma Inc ATYR
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is aTyr Pharma (ATYR) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of $0.53 is trading 14.7% above its estimated GF Value™ of $0.46. GuruFocus considers aTyr Pharma to be Modestly Overvalued.

Key valuation signals for ATYR:

  • Valuation Rank:
  • GF Value™: $0.46 vs. price of $0.53 (14.7% above fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

aTyr Pharma Business Description

Other Exchanges 471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score

Get the complete analysis for ATYR

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.53
Price
$0.46
GF Value